Table 2 Drug treatment in 71 JIA patients 24 months before and 24 months after the initiation of the anti‐TNF treatment.
| Treatment | 24 Months before | Initiation of anti‐TNF treatment | 24 Months after |
|---|---|---|---|
| DMARDs and other drug treatments | |||
| Hydroxychloroquine | 23 (32%) | 30 (42%) | 17 (24%) |
| Methotrexate | 46 (65%) | 62 (87%) | 58 (82%) |
| Ciclosporine | 17 (24%) | 32 (45%) | 8 (11%) |
| Sulfasalazine | 15 (21%) | 18 (25%) | 4 (6%) |
| Azathioprine | 6 (8%) | 10 (14%) | 7 (10%) |
| Gold sodium thiomalate | 5 (7%) | 6 (8%) | 1 (1%) |
| Auranofin | 1 (1%) | 0 | 0 |
| Podophyllotoxin | 1 (1%) | 3 (4%) | 0 |
| Leflunomide | 0 | 0 | 5 (7%) |
| Intravenous immunoglobulin | 1 (1%) | 0 | 1 (1%) |
| Prednisolone | 46 (65%) | 55 (77%) | 33 (46%) |
| Treatment strategy | |||
| No DMARDs | 16 (23%) | 2 (3%) | 4 (6%) |
| Prednisolone alone | 0 | 1 (1%) | 0 |
| Single treatment (1 DMARD) | 1 (1%) | 2 (3%) | 25 (35%) |
| Single DMARD with prednisolone | 10 (14%) | 10 (14%) | 17 (24%) |
| Combination treatment | 9 (13%) | 13 (18%) | 9 (13%) |
| Combination treatment with prednisolone | 35 (49%) | 44 (62%) | 16 (23%) |
Values are n (%).
DMARD, disease modifying anti‐rheumatic drug; JIA, juvenile idiopathic arthritis; TNF, tumour necrosis factor.